Insulin Detemir in Obesity Management

Running, not enrolling · Not applicable

Conditions studied: Diabetes, Obesity

In brief

The purpose of this study is to evaluate the effects of the medication insulin detemir on weight, brain function and mood, and on blood vessel and other risk factors for heart disease. The study will compare how diet and insulin detemir affect areas of the brain that are involved in food intake and the sense of pleasure people get from eating. Participants will be randomized into one of 2 groups. Group 1 will follow a low calorie diet only. Group 2 will follow a low calorie diet and take insulin detemir. The study is 26 weeks in length and include outpatient visits, inpatient visits, phone and email contact, questionnaires, diary collection, blood draw and procedures involving MRI and PET scans. There are 4 inpatient visits at the Vanderbilt Clinical Research Center (CRC). The inpatient visits require a one night 2 day stay on the CRC at Weeks 2, 6, 16, 26. During the weekly and bi-weekly outpatient visits participants will meet with the study nurse and dietitian.

Key facts

Study ID

NCT01239550

Run by

Vanderbilt University

People needed

240

Starts

2011-04-01

Expected to finish

2028-12-01

Last updated by the study team

2026-01-23

Who can join

Age: 31 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Informed consent obtained before any trial-related activities
• Age at study entry is between 31-60 years of age
• Body Mass index (BMI) between 30-49 kg/m2 using measured height and weight
• Body weight <350lbs (MRI table limit)
• Stable body weight during the previous 3 months with a less than 5 pounds self -reported weight change
• Type 2 diabetes, insulin naïve (except for use during gestational diabetes) on either metformin, sitagliptin, or dipeptidyl-4 inhibitor (sitagliptin or saxagliptin), or a thiazolidines (rosiglitazone or pioglitazone)
• HbA1c level between \~6-8%
• Lives in a community dwelling and has a telephone
• Agrees to avoid alcohol and exercise within 48 hours of CRC visits, and to comply with the dietary/stimulant restrictions for 48 hours before PET and fMRI studies.
• Able and willing to follow prescribed menus plans

You may not qualify if…

• Known or suspected hypersensitivity to study drug (insulin detemir)
• Significant co-morbidities including cardiovascular disease, atherosclerotic disease, pulmonary disease, metabolic disease, liver or renal insufficiency
• Significant pathologic finding on MRI (research MRI scans are not clinical scans and are not standardly read by a neuroradiologist, but if an overt anomaly is noted by study personnel, an advisory read will be obtained and the patient will be provided with the information for follow-up with his/her physician).
• Clinically significant abnormalities on screening EKG
• History of Substance Abuse, including but not exclusive to alcohol, cocaine, marijuana, heroin, nicotine
• Any tobacco use in last 3 months
• History of psychiatric disorder deemed too severe to permit participation (PI discretion) including subjects with a lifetime history of lifetime Psychotic Disorder (Schizophrenia, Schizoaffective, Psychosis NOS) or Bipolar Disorder, suicide attempt or history of any suicidal behavior or history within the past 6 months of Post Traumatic Stress Disorder, Generalized Anxiety Disorder
• Long term use of steroids or medications that may cause weight gain within 3 months of study or in foreseeable need (e.g. uncontrolled asthma or rheumatologic disorder).
• Inability to abstain from alcohol, physical exercise or > 1 cup of coffee or equivalent daily for 2 days prior to imaging studies
• Any contraindication which would interfere with MRI or PET studies, e.g. claustrophobia, cochlear implant, metal fragments in eyes, cardiac pacemaker, neural stimulator, tattoos with iron pigment and metallic body inclusions or other metal implanted in the body
• Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (abstinence or the following methods: diaphragm with spermicide, condom with spermicide by male partner, intrauterine device, sponge, spermicide, Norplant, Depo-Provera or oral contraceptives)
• History of uncontrolled thyroid disease evidenced by TSH outside normal range
• Obesity induced by other endocrinologic disorders (e.g. Cushing Syndrome, Polycystic ovarian syndrome)
• Previous surgery for weight loss
• High level aerobic activity such as running for longer than 60 minutes more than 2 times a week regularly in last 3months
• Significant eating disorder or dietary restraints as determined by three factor eating questionnaire (TFEQ)
• Appetite reducing diet supplement or herbal supplement use in last 6 months
• . Food allergy or diet restrictions that would interfere with balanced intake and caloric goals.
• Dietary supplements of such as EPA, DHA or omega-3 fatty acids.
• Daily intakes of coffee, black tea and other caffeinated beverages will be assessed and subjects who consume the equivalent of >4 cups coffee or black tea/day at baseline will be excluded
• Any condition felt by PI or co-investigators to interfere with ability to complete the study

Where it is running

• Vanderbilt University — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.